Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Jeffrey Grace, MD
Buffalo Psychiatric Center
Principal Investigator - Nigel Bark, MD
Bronx Psychiatric Center
Principal Investigator - Steven Schwarzkopf, MD
Rochester Psychiatric Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Buffalo Psychiatric Center
Buffalo, New York, United States
- Bronx Psychiatric Center
The Bronx, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2005
- Primary completion
- 30 Apr 2008
- Completion
- 30 Apr 2008
- Last update posted
- 1 May 2020
- Registered enrollment
- 40
- Registry id
- NCT00458211
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.